Clinical Trials
2 trialsNCT01931098 2025-08-11
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00459381 2017-03-15
Pazopanib in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Completed